医学
心肌梗塞
不稳定型心绞痛
观察研究
急诊医学
心力衰竭
内科学
心绞痛
死亡率
前瞻性队列研究
重症监护医学
作者
Runlin Gao,Anushka Patel,Wei Gao,Dayi Hu,Dong Huang,Ling Yuan Kong,Wei Qi,Yangfeng Wu,Yue Yang,Philip J. Harris,Charles S. Algert,P. Groenestein,F. Turnbull
出处
期刊:Heart
[BMJ]
日期:2007-10-11
卷期号:94 (5): 554-560
被引量:93
标识
DOI:10.1136/hrt.2007.119750
摘要
Objective: To describe the investigation and management of patients admitted to hospitals in China with suspected acute coronary syndromes (ACS) and to identify potential areas for improvement in practice. Design: A multicentre prospective survey of sociodemographic characteristics, medical history, clinical features, in-hospital investigations, treatment practices and major events among patients with suspected ACS. Setting: Large urban public hospitals. Patients: Consecutive patients admitted to in-patient facilities with a diagnosis of suspected acute myocardial infarction (MI) or unstable angina pectoris. Main outcome measures: Myocardial infarction/re-infarction, heart failure, death. Results: Between September 2004 and May 2005, data were collected prospectively from 2973 patients admitted to 51 hospitals in 18 provinces of China. An initial diagnosis of ST elevation MI, non-ST elevation MI and unstable angina was made in 43%, 11% and 46% of patients, respectively. Diagnosis was inconsistent with objective measures in up to 20% of cases. At both tertiary and non-tertiary centres, there was little evidence that clinical risk stratification was used to determine the intensity of investigation and management. The mortality rate during hospitalisation was 5% overall and similar in tertiary and non-tertiary centres, but reported in-hospital re-infarction rates (8%) and heart failure rates (16%) were substantially higher at non-tertiary centres. Conclusion: This study has identified a number of areas in the management of ACS patients, including diagnosis and risk stratification, which deviate from current guidelines. These findings will help inform the introduction of widely used quality improvement initiatives such as clinical pathways.
科研通智能强力驱动
Strongly Powered by AbleSci AI